Evestia Clinical buys Belgium's Emtex to deepen European reach
What's the deal? London-based Evestia ClinicalDealroom has a profile for this one. Try Dealroom →, an independent global contract research organisation (CRO), has acquired EmtexDealroom has a profile for this one. Try Dealroom → Life Science, a Belgian specialist in regulatory medical writing. Terms were not disclosed. The deal, announced November 3, expands Evestia Clinical's European footprint and its full-service clinical research offering.
What each side brings: Emtex, with more than 25 years of experience, prepares clinical study reports, trial protocols, investigator brochures, and regulatory documentation for pharmaceutical and biotech clients. Evestia Clinical already offers medical writing as part of a broader portfolio spanning oncology, neurology, and rare diseases.
What's the endgame? The move adds scale to Evestia Clinical's existing medical writing team. "Emtex's established expertise in regulatory medical writing and scientific communications complements and further enhances our existing capabilities," said chairman Richard Barfield.
Why now? This is Evestia Clinical's latest acquisition-led expansion. In January 2026 it bought Germany's ICRC-WeyerDealroom has a profile for this one. Try Dealroom →, adding biostatistics, data management, and medical-writing expertise.
Emtex will keep its services and teams unchanged. Chief executive officer Mario De Witte and head of QA Mieke Notenbaert will continue to run the business. "Becoming part of Evestia Clinical gives us the opportunity to build on these foundations," De Witte said.
The signal: The wider CRO market is consolidating, from FortreaDealroom has a profile for this one. Try Dealroom →'s $45 million purchase of Worldwide Clinical TrialsDealroom has a profile for this one. Try Dealroom →' early-phase unit to McKesson's roughly $2.25 billion agreement to buy Precision Medicine GroupDealroom has a profile for this one. Try Dealroom →. Against that backdrop, Emtex is a targeted European tuck-in that deepens Evestia Clinical's regulatory writing muscle rather than a large-scale combination.
Read more: globenewswire.com
Image credit: National Institutes of Health (NIH)
